Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediWoundMDWD +0.30%56 3-Year Book Growth Rate is 31.10% as of Jun. 2026, which is 2204% above its 10-year median of 1.35. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $11.09 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,128 Biotechnology companies, MediWound ranks better than 89.27% on this metric.
During the past 12 months, MediWound's average Book Value per Share Growth Rate was 49.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 31.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of MediWound was 31.10% per year. The lowest was -43.70% per year. And the median was 1.35% per year.
MediWound (NAS:MDWD) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
MediWound 3-Year Book Growth Rate Related Terms
MDWD vs LENZ, OTLK, OKUR: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, MediWound's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where MediWound's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 31.10% mean?
MediWound (MDWD) has a 3-Year Book Growth Rate of 31.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for MediWound and its competitors. This is 2204% above median its historical median of 1.35. According to the industry distribution chart, MediWound ranks #121 out of 1128 companies in the Biotechnology industry, placing it in the top 10.7%.
Is MediWound's 3-Year Book Growth Rate too high?
MediWound's current 3-Year Book Growth Rate of 31.10% is 2204% above median its 10-year median of 1.35. Based on the distribution chart, MediWound ranks #121 out of 1128 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's 3-Year Book Growth Rate compare to LENZ and OTLK?
According to the Biotechnology industry distribution chart, MediWound ranks #121 out of 1128 companies for 3-Year Book Growth Rate. This places MediWound in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for MediWound and its competitors. MediWound's current 3-Year Book Growth Rate is 31.10%, which is 2204% above median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $11.09, compared to a current price of $13.31 — trading 20% above its estimated fair value. The current 3-Year Book Growth Rate is 31.10%, which is 2204% above median its 10-year median of 1.35. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For MediWound (MDWD), the current 3-Year Book Growth Rate is 31.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $13.31 is trading 20% above its estimated GF Value™ of $11.09.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
3-Year Book Growth Rate: 31.10% (2204% above median its 10-year median of 1.35)
GF Value™: $11.09 vs. price of $13.31 (20% above fair value)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for MDWD
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
